Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells 58,424 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) insider John Paolini sold 58,424 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the sale, the insider owned 65,623 shares of the company’s stock, valued at $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock traded down $0.88 during midday trading on Tuesday, reaching $56.74. The company had a trading volume of 624,640 shares, compared to its average volume of 710,959. The stock has a fifty day moving average price of $46.40 and a 200 day moving average price of $43.20. The firm has a market cap of $4.34 billion, a PE ratio of 63.04 and a beta of 0.17. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $24.85 and a fifty-two week high of $58.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same quarter in the prior year, the firm posted $0.11 earnings per share. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.22 EPS for the current year.

Analyst Upgrades and Downgrades

KNSA has been the topic of several analyst reports. Canaccord Genuity Group lifted their target price on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Monday. Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, April 21st. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $60.86.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. Rubric Capital Management LP grew its position in Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after buying an additional 90,194 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after acquiring an additional 49,802 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Kiniksa Pharmaceuticals International by 45.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after acquiring an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares in the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.